Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse. Frontline lenalidomide therapy has increased the number of patients with lenalidomide-refractory disease at the time of the first relapse. METHODS: In this phase 3, randomized, open-label trial, we evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd), as compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients who had relapsed or refractory myeloma after at least one line of therapy. The primary end point was progression-free survival. Disease response and safety were also assessed. RESULTS: A total of 302 patients underwent randomization; 155 were assigned to the BPd group, and 147 to the PVd group. At a median follow-up of 21.8 months (range, <0.1 to 39.2), the 12-month estimated progression-free survival with BPd was 71% (95% confidence interval [CI], 63 to 78), as compared with 51% (95% CI, 42 to 60) with PVd (hazard ratio for disease progression or death, 0.52; 95% CI, 0.37 to 0.73; P<0.001). Data on overall survival were immature. The percentage of patients with a response to treatment (partial response or better) was 77% (95% CI, 70 to 84) in the BPd group and 72% (95% CI, 64 to 79) in the PVd group; 40% (95% CI, 32 to 48) and 16% (95% CI, 11 to 23), respectively, had a complete response or better. Grade 3 or higher adverse events occurred in 94% of the patients in the BPd group and 76% of those in the PVd group. Ocular events occurred in 89% of the patients who received BPd (grade 3 or 4 in 43%) and 30% of those who received PVd (grade 3 or 4 in 2%); ocular events in the BPd group were managed with belantamab mafodotin dose modification. Ocular events led to treatment discontinuation in 9% of the patients in the BPd group and in no patients in the PVd group. CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, 2018-004354-21.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two recent phase III studies have shown significant benefit with belantamab (Table 9), and hence it is likely the drug will be reapproved in the near future with better recommendations for dosing and dose frequency.162,163”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [163]
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [26]
In the citing paper
“Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [26]
In the citing paper
“Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [26]
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405090 · Cited by 199
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer · doi:10.1002/cncr.33809 · Cited by 144
Self-citationLonial, S., Nooka, A. K., Thulasi, P., Badros, A. Z., Jeng, B. H., Callander, N. S., Potter, H. A., Sborov, D., Zaugg, B. E., Popat, R., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00494-4 · Cited by 89
Self-citationNavigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabo, Z., & Garderet, L. (2019) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 79
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M.-V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationCurrent Treatment Strategies for Multiple Myeloma
Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 60
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“Ocular AEs led to treatment discontinuation in 9% of the patients in the BelaPd arm 98,99 .”
Self-citationTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119
“…mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM. 26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular…”
InfluentialSelf-citationCosta, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 101
Einsele, H., San‐Miguel, J., Dhakal, B., Touzeau, C., Leleu, X. P., van de Donk, N. W. C. J., Sidana, S., Oriol, A., Cohen, Y. C., Harrison, S. J., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00653-9 · Cited by 70
Self-citationZhou, K., Liu, X., & Zhu, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01752-9 · Cited by 63
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 41
“The B-Pd regimen was associated with an increased ORR of 77% versus 72% with B-Pd and a complete response or stringent complete response (CR/sCR) in 40% versus 16% of patients 32 .”
InfluentialHu, X., Zhang, Q., Wang, L., Zhang, J., Ouyang, Q., Wang, X., Li, W., Xie, W., Tong, Z., Wang, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02149-3 · Cited by 46
The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050
Dou, X., Duan, G., Zhong, Y., Liu, Y., Peng, N., Lei, W., Qi, J., Zhou, M., Zhang, X., & Lu, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217440 · Cited by 39
Ntanasis‐Stathopoulos, I., Filippatos, C., Ntanasis‐Stathopoulos, A., Malandrakis, P., Kastritis, E., Tsitsilonis, O., Dimopoulos, M. A., Terpos, E., & Gavriatopoulou, M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27582 · Cited by 32
Self-citationvan de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M. M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 33
“32,33 Patients might be ineligible for CAR T-cell therapy because of frailty or comorbidities, such as cardiac disease or neurological disorders.”
Self-citationTeclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 39
Self-citationGay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 37
“Over the past year, two recent Phase III studies, DREAMM‐7 [74] and DREAMM‐8 [75], have shown a significant PFS benefit of belantamab in combination with either bortezomib or pomalidomide, respectively, as a second‐line or later treatment.”
Mateos, M., Trudel, S., Quach, H., Robak, P. J., Beksaç, M., Pour, L., Hus, M., Kım, K., Анатольевна, Ж. В., Delimpasi, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016949 · Cited by 24
Self-citationvan de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70260 · Cited by 26
“4,13,15,16 There are currently two BCMA ‐ directed CAR T ‐ cell therapies approved for the treatment of patients with relapsed/refractory MM (cilta ‐ cel in patients with lenalidomide ‐ refractory MM after ≥ 1 prior treatment line, and ide ‐ cel for patients with triple ‐ class ‐ exposed MM after ≥…”
InfluentialSelf-citationMukhopadhyay, P., Abdullah, H. A., Opalinska, J., Paka, P., Richards, E., Weisel, K. C., Trudel, S., Mateos, M., Dimopoulos, M. A., & Lonial, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01212-0 · Cited by 23
“…understanding of the response I n t e r i m A n a l y s i s [ 18 ] U pd a t e d A n a l y s i s [ 33 ] I n t e r i m A n a l y s i s [ 22 ] 2 n d I n t e r i m A n a l y s i s [ 21 ] RR M M mechanisms that would expect to lead to PFS outcomes improving in favor of belantamab mafodotin over time.”
InfluentialSelf-citationCardiomyopathy: pathogenesis and therapeutic interventions
Huang, S., Li, J., Li, Q., Wang, Q., Zhou, X., Chen, J., Chen, X., Bellou, A., Zhuang, J., & Lei, L. (2024) · MedComm · doi:10.1002/mco2.772 · Cited by 25
Self-citationHartley-Brown, M. A., Weisel, K. C., Bitetti, J., Carter, J. A., McNamara, S., Purser, M. F., Palumbo, A., & Richardson, P. G. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19627 · Cited by 20
“…myeloma cells, B cell maturation antigen (BCMA) and protein–coupled receptor class C group 5 member D (GPRC5D) are promising targets in RRMM. 88,89 104 The strengths of this study include that the study protocol was pre-registered with PROSPERO, ensuring trans-parency of the methods and adherence…”
Characterization of Belantamab Mafodotin–Induced Corneal Changes in Patients With Multiple Myeloma
Lee, V., Hultcrantz, M. L., Petrone, S., Lewis, E., Banna, H., Lichtman, E. I., Thulasi, P., Quick, A., Jeng, B. H., Sunshine, S. B., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1008 · Cited by 18
Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events
Terpos, E., Trudel, S., Mateos, M., Alejandre‐Alba, N., Colby, K. A., Dimopoulos, M. A., Esposti, S. D., Farooq, A. V., Gavriatopoulou, M., Gay, F., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70015 · Cited by 15
“…versus n = 251 daratumumab, bortezomib, and dexamethasone [median follow-up 28.2 months]; DREAMM-8: n = 155 belamaf in combination with pomalidomide and dexamethasone versus n = 147 poma-lidomide, bortezomib, and dexamethasone [median follow-up 22.4 versus 20.5 months, respectively]) [6, 7].”
InfluentialSelf-citationUpdates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 18
“Recently published data by the DREAMM-8 investigators [30] demonstrated an improved, durable, and deep PFS with Belantamab mafotodin, Pomalidomide and Dexamethasone (BPD) group compared to bortezomib, pomalidomide, and dexamethasone (PVd), especially amongst lenalidomide-exposed patients.”
BackgroundBruins, W. S. C., Smits, F., Duetz, C., Groen, K., Korst, C. L. B. M., de Jonge, A. V., Verkleij, C. P. M., Rentenaar, R., Cosovic, M., Eken, M., et al. (2025) · Blood · doi:10.1182/blood.2025028587 · Cited by 14
Koo, S., Kim, C. Y., Lim, J.-H., Lee, E., Kim, I. Y., Shin, Y. G., & Moon, H. (2025) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2025.33.e21 · Cited by 15
“In contrast, belantamab mafodotin (Blenrep) was retained, given its continued clinical investigation and active resubmission process despite market withdrawal after failure in a confirmatory trial [13-15].”
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Jureczek, J., Kałwak, K., & Dzięgiel, P. (2024) · Cancers · doi:10.3390/cancers16244181 · Cited by 16
“Similarly, the BelaMaf-based combination demonstrated superior performance compared to the control group in response rate, response durability, and PFS [136].”
Yee, A. J., Laubach, J. P., Campagnaro, E. L., Lipe, B. C., Nadeem, O., Friedman, R. S., Cole, C. E., O’Donnell, E., Bianchi, G., Branagan, A. R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014717 · Cited by 18
“32 With these considerations, elo-PVd may emerge as a viable alternative when there is limited access to CAR T-cell therapies or bispeci fi c antibodies.”
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Mancuso, K., Barbato, S., Raimondo, F. D., Gay, F., Musto, P., Offidani, M., Petrucci, M. T., Zamagni, E., Zambello, R., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17071168 · Cited by 10
“…ADC belantamab mafodotin (B), initially tested as monotherapy in the DREAMM-2 trial [84] and subsequently compared with Pd in the DREAMM-3 study [85], was further evaluated in the large phase 3 randomized trials DREAMM-7 and DREAMM-8 in the setting of len-exposed and len-refractory RRMM…”
Self-citationEngineering de novo binder CAR-T cell therapies with generative AIPreprint
Mergen, M., Abele, D., Koleci, N., Fernandez, A. S., Sugden, M., Holzleitner, N., Carr, A., Rieger, L., Leone, V., Reichert, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.25.625151 · Cited by 16
Lebel, E., Vainstein, V., Milani, P., Palladini, G. O., Shragai, T., Lavi, N., Magen, H., Assayag, M., Avivi, I. M., & Gatt, M. E. (2024) · Acta Haematologica · doi:10.1159/000541594 · Cited by 10
“The recent extensive experience with BLM in DERAMM-7 and DREAMM-8 studies in MM is supportive of general approach to corneal toxicity with BLM, but the ideal dosing approach is still under debate [12, 13].”
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Touzeau, C., Leleu, X. P., Tiab, M., Macro, M., Perrot, A., Gay, J., Chateleix, C., Moreau, S., Karlin, L., Jacquet, C., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.19978 · Cited by 13
“17,20 Cilta-cel and ide-cel demonstrated strong activity in RRMM from first or second relapse.”
InfluentialTreatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Novel Treatment Options for Multiple Myeloma
Portuguese, A. J., Banerjee, R. K., Chen, G. Z., Reddi, S., & Cowan, A. J. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00752 · Cited by 17
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis
Jamroziak, K., Zielonka, K., Khwaja, J., & Wechalekar, A. D. (2025) · British Journal of Haematology · doi:10.1111/bjh.19960 · Cited by 12
“However, results of trials combining belantamab with bortezomib 51 and poma-lidomide 52 show very promising results.”
Papathanasiou, T., Kaullen, J. D., Polireddy, K., Chen, X., Ho, Y. L., Taylor, A. B., Struemper, H., Carreño, F., & Ferron‐Brady, G. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01508-1 · Cited by 11
“…dexamethasone versus daratumumab with bort-ezomib and dexamethasone (hazard ratio [HR] 0.41 [95% CI 0.31–0.53]) and the DREAMM-8 (NCT04484623) trial of belantamab mafodotin with pomalidomide and dexamethasone versus pomalidomide with bortezomib and dexamethasone (HR 0.52 [95% CI 0.37–0.73]) [5, 6].”
InfluentialCani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.003 · Cited by 8
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00927-6 · Cited by 8
Popat, R., Augustson, B. M., Gironella, M., Lee, C., Cannell, P., Patel, N., Kasinathan, R. S., Rogers, R., Shaikh, M., Curry, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01155-y · Cited by 10
“A positive trend in overall survival (OS) was also demonstrated in both studies [9].”
ResultSelf-citationCurrent Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
“Subgroup analysis showed that the improvement in PFS was also observed in patients refractory to anti-Cd38 antibodies, nevertheless, without reaching statistical significance (42.9% 12-month PFS vs. 30.6% 12-month PFS; (HR, 0.65; 95% CI, 0.36–1.18) [39].”
InfluentialDileo, R., Mewawalla, P., Babu, K., Yin, Y., Strouse, C. S., Chen, E., Shaikh, H. G., Davis, J. A., Green, K. M., Alkharabsheh, O. A., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01226-8 · Cited by 9
“However, data from recent phase III randomized controlled trials (DREAMM-7 and DREAMM-8) [6, 7] demonstrated signi fi cant improvements in depth and duration of response with belantamab mafodotin combination therapies when compared to standard-of-care treatments for RRMM.”
Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17091514 · Cited by 12
“…lines—in the near future, and given the increase in treatment options, thanks to the availability of combinations based on the anti-BCMA antibody-drug conjugate belantamab mafodotin, whose toxicity profile appears to be more manageable and better adaptable, even for frail patients [134–137].”
Self-citationHuman preclinical multiple myeloma in vitro models for disease modeling and therapy screening
Ybarra, M., Lee, J., Chen, Y.-Y., Lin, J., Zhao, J., & Ma, C. (2025) · Journal of Biological Engineering · doi:10.1186/s13036-025-00570-4 · Cited by 8
“…immunomodulatory drugs (IMiDs) that can amplify immune response, monoclonal antibodies to directly induce apoptosis, and other immunotherapy treatments such as chimeric antigen receptor (CAR) T-cell therapy that targets MM specific markers such as B-cell maturation antigen (BCMA) [25–34].”
Terpos, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Solia, E., et al. (2025) · Blood · doi:10.1182/blood.2025031629 · Cited by 7
Self-citationDiaz, A. A., Alouch, S. S., Chawla, Y., & Gonsalves, W. I. (2024) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s490021 · Cited by 13
Ntanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Koutoulidis, V., Trapali, M., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Leukemia · doi:10.1038/s41375-025-02677-5 · Cited by 8
Self-citationA Belantamab Mafodotin Revival in Multiple Myeloma Therapy
Trudel, S., & Stewart, A. K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406799 · Cited by 6
Self-citationApproaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Hultcrantz, M. L., Derkach, A., Hassoun, H., Korde, N., Maclachlan, K. H., Mailankody, S., Patel, D., Shah, U. A., Tan, C. R. C., Chung, D. J., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100103 · Cited by 18
“10,11 As clinical trials have strict inclusion/exclusion criteria, the trial population does not necessarily re fl ect the entire population of patients with relapsed/refractory multiple myeloma.”
Feng, X., Yu, X., Yang, S., Yuan, G., Huang, M., He, Z., & Wu, J. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01447-6 · Cited by 7
Mewawalla, P., Dileo, R., Yin, Y., Strouse, C. S., Shaikh, H. G., Davis, J. A., Alkharabsheh, O. A., Rashid, A., Ahmed, N., Abdallah, A.-O. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.015 · Cited by 9
Dimopoulos, M. A., Beksaç, M., Pour, L., Delimpasi, S., Vorobyev, V. I., Quach, H., Spicka, I., Radocha, J., Robak, P. J., Kim, K., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00256-x · Cited by 7
Self-citationClinical applications of antibody-drug conjugates in advanced non-small cell lung cancer
Guo, H., Xu, Z., Li, K., Guo, C., Lin, F., Pu, Q., & Wang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787148 · Cited by 8
“…toxicities (e.g., myelosuppression, peripheral neuropathy), which force the maximum tolerated dose near the minimum effective dose, these ADCs payloads exhibit a narrow therapeutic index (or window) and consequently have limited ef fi cacy against tumors with low antigen expression (16, 60 – 65).”
Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions
Li, S., Wang, H., Xiong, S., Liu, J., & Sun, S. (2024) · Pharmaceuticals · doi:10.3390/ph17070832 · Cited by 9
“Concurrently, the phase 3 clinical trial DREAMM-8 demonstrated that the combination of belantamab mafodotin, pomalidomide, and BTZ has significant benefits in terms of PFS [31].”
BackgroundCurrent State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Lal, B. M., van Rhee, F., & Hadidi, S. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01639-5 · Cited by 8
“The benefit was maintained in patients with high-risk disease and frail patients [118].”
Korst, C. L. B. M., Plattel, W. J., de Kort, E., Smits, F., Croockewit, A. J., Levin, M., Westerman, M., de Weerdt, O., Nijhof, I. S., Wegman, J. J., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00298-4 · Cited by 7
Dimopoulos, M. A., Schjesvold, F. H., Fu, C., Hartley-Brown, M. A., Gomez, C., Reece, D. E., Mikala, G., Alkharabsheh, O., Parrish, C., Crusoé, E. D. Q., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01088-3 · Cited by 9
Self-citationLal, B. M., Alzubi, M., Alrawabdeh, J. A., Shaughnessy, J. D., Zhan, F., Siegel, E. R., Schinke, C., Thanendrarajan, S., Zangari, M., van Rhee, F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015648 · Cited by 8
Beksaç, M., Şahlı, E., Rabea, A. M., Saydam, G., Tombak, A., Alhuraiji, A., Mutahar, E. Y., Hosny, M., Alhejazi, A., Mattar, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.019 · Cited by 6
Boytsov, N. N., McGuiness, C. B., Zhou, Z., Huo, T., Montgomery, K., Kotowsky, N., & Chen, C. (2025) · Future Oncology · doi:10.1080/14796694.2025.2504318 · Cited by 5
“The BCMA-targeting antibody-drug conjugate belantamab mafodotin is being evaluated in combination regimens for early LOTs and has shown progression-free survival (PFS) benefits in phase 3 RRMM studies [56,57].”
Martino, E. A., Caridà, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105514 · Cited by 7
First case report of talquetamab use in AL amyloidosis
Even‐Zohar, N. G., Aumann, S., Shaulov, A., Haran, A., Nachmias, B., Lebel, E., Lehmann‐Werman, R., & Gatt, M. E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2556175 · Cited by 5
“…the new-est targets in the treatment of MM. Targeting BCMA with antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell, and recently bispecific T cell engagers (BiTEs) have become the mainstay of RRMM therapy yet have been scarcely reported in patients with AL amyloidosis [10–16].”
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review
Pan, D., Kumar, A. D., Lipof, J. J., Chung, A., Wolf, J. L., Martin, T. G., Arora, S., Sayre, P. H., & Chari, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511179 · Cited by 6
Hungria, V., Polo, V. A., Corzo, A., Crusoé, E., Farah, M. E., Iutaka, N. A., Martınez, G., Ramírez-Alvarado, A. G., Romano-Bucay, S., Schlottmann, P. G., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00354-2 · Cited by 4
Watson, E. C. R., Shuwa, H. A., Heycock, M. W. D., Wade, J., Wang, C.-Y., Htun, M., Li, L., Niehaus, V., Baker, W., Miller, B., et al. (2026) · BMJ Immunology · doi:10.1136/bmjimm-2026-000029 · Cited by 8
Hanafin, P., Ho, Y. L., Papathanasiou, T., Fulci, G., Sule, N., Kremer, B. E., & Ferron‐Brady, G. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01174-0 · Cited by 4
“In the DREAMM-8 study, dose modifications led to extended belantamab mafodotin dosing intervals with time on treatment, with corresponding reduction in belantamab mafodotin dose intensity [6].”
InfluentialSelf-citationWu, S., Huang, C., Chen, X.-D., Liu, Q.-T., Chen, L., Wang, S.-P., Hu, J., & Liu, Z. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003603 · Cited by 4
Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4
“Recovery is reported in 77–94% of patients [19, 22, 25, 27].”
InfluentialGan, X., Li, L., Zhang, L., Zheng, Y., Niu, T., & Yu, Z. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01199-z · Cited by 4
Mele, G., Sgherza, N., Pastore, D., & Musto, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206238 · Cited by 5
Rodriguez, C., Rodriguez, T. E., Kentos, A., Driessen, C., Suanmi, K., Lesokhin, A. M., Yee, A. J., Minella, A. C., Maraboina, R., Upreti, V. V., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2528115 · Cited by 4
“[45,46] and grade ≥3 CRS (4–5”
Self-citationEncinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 9
Self-citationRüsing, L. Z., Schweighofer, J., Aschauer, J., Jeryczynski, G., Vospernik, L., Gisslinger, H., Bumberger, A. M., Cserna, J., Riedl, J., Agis, H., et al. (2025) · Cancers · doi:10.3390/cancers17142398 · Cited by 3
“In DREAMM-7 and DREAMM-8, keratopathy was also commonly observed but effectively managed through dose modifications and resolved within 9–12 weeks, consistent with our observations (median 10 weeks) [12].”
Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
Hong, S.-Y., Lu, W.-R., Chen, X.-D., Rao, H.-Y., & Chen, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-10924-z · Cited by 5
“If necessary, treatment regimens should be adjusted based on the patient’s ocular status to ensure both the safety and continuity of therapeutic management 36,37 .”
Rees, M. J., Xu, T. T., Atallah‐Yunes, S. A., Lim, K. J. C., Ailawadhi, S., Parrondo, R. D., Fonseca, R., Bergsagel, P. L., Hayman, S. E., Dispenzieri, A. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.003 · Cited by 3
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
Chakraborty, R., Bhutani, D., & Lentzsch, S. (2025) · Hematology · doi:10.1182/hematology.2025000760 · Cited by 3
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Lal, B. M., & Kumar, S. K. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00771-8 · Cited by 3
Costa, B. A., Costa, T. A., Chagas, G. C. L., Mouhieddine, T. H., Richter, J. R., Usmani, S. Z., Mailankody, S., Rajeeve, S., & Hashmi, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.09.008 · Cited by 3
Richter, J. R., Nooka, A. K., Rodríguez‐Otero, P., Schjesvold, F. H., Katodritou, E., Combe, E., Scott, M., Cooper, L., Sly, I., Ballew, N., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27661 · Cited by 3
“6], and preclinical synergy observed between belantamab mafodotin with pomalidomide and with bortezomib [7], additional phase 3 trials, DREAMM-7 [8] and DREAMM-8 [9], investigated belantamab mafodotin in different combination regimens versus standard of care.”
Moore, S. E., Miller, H., Parrish, C., Seymour, F., Miller, L. J., Chandler, T., Land, J., Karpha, I., Brearton, G., Thompson, S., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70041 · Cited by 6
“74 and that this toxicity did not impact on patient assessed quality of life in either study.”
InfluentialWatson, E. C. R., Djebbari, F., Panitsas, F. P., Vallance, G. D., Asher, S., Saeed, M., Walker, M., Powell, M., Rampotas, A., Leary, H., et al. (2025) · eJHaem · doi:10.1002/jha2.70039 · Cited by 2
Advances in NK cell therapy for multiple myeloma
Liu, N., Zeng, Y., Wang, Y., Wang, C., Li, N., & Xu, J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101639 · Cited by 3
Sunami, K., Fujisaki, T., Funaki, T., Ichii, M., Ito, S., Matsumoto, M., Oshima, K.-I., Suzuki, K., & Takakuwa, T. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf148 · Cited by 3
“The majority of patients treated with belantamab mafodotin in clinical trials experienced OAEs [7, 8].”
InfluentialSelf-citationRizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 4
“…of len-exposed and high percentages of len-ref patients (71% for PVd, 23% of whom at first relapse, 79% for DaraPd, and 81% for BelaPd) [13, 14, 19], and the CARTITUDE-4 trial was subsequently designed for len-ref patients (enrolling 32.7% of len-ref at first relapse) 17, these patients were…”
InfluentialSelf-citationHuang, X., Wu, X., Chen, W., Wang, W., Xu, W., Guo, J., Zhao, J., Xu, X., Wang, C., Shan, A., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001096 · Cited by 2
Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K. C., Straßl, I., Krauth, M. T., Knop, S., Winder, T., & Steiner, N. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07140-8 · Cited by 4
Moore, S. E., Cornic, L., Crossman-Barnes, C.-J., José, S., Khalaf, Z., Yong, K., Soutar, M., & Woods, P. (2024) · eJHaem · doi:10.1002/jha2.1058 · Cited by 2
Chari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 4
Patel, M. N., Locke, S. C., Falvey, C. A., Troy, J. D., Herring, K. W., Bolgioni, A. F., Elcock, C. H., Iadeluca, L. L., Chase, C. C., Gasparetto, C., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.008 · Cited by 5
Katodritou, E., Terpos, E., Lentzsch, S., & Kumar, S. K. (2025) · American Journal of Hematology · doi:10.1002/ajh.27646 · Cited by 3
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region
Alhuraiji, A., Farsi, K. A., Mheidly, K., Elsabah, H., Cherif, H., Hamad, A. A., Marashi, M., Al-Hateeti, H., Osman, H. Y., & Mohty, M. (2025) · Clinical Hematology International · doi:10.46989/001c.137860 · Cited by 3
Ntanasis‐Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.003 · Cited by 3
Self-citationYi, J. H., Yoon, D. H., & Kım, K. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.003 · Cited by 2
Duration of Response as Clinical Endpoint: A Quick Guide for Clinical Researchers
Kim, S., Kim, M.-J., & Choe, J. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0589 · Cited by 2
“On the other hand, if there is interest in DOR for the patients who have not been administered the new therapy, then those patients who received new therapy are censored at the last response assessment before the start of the new therapy [2,3,8].”
BackgroundHo, P. J., & Li, E. W. (2025) · Internal Medicine Journal · doi:10.1111/imj.16647 · Cited by 2
McCurdy, A. B. R., Gul, E., Reece, D. E., Chu, M. P., Jimenez-Zepeda, V. H., Louzada, M., Song, K., Mian, H. S., Sébag, M., White, D. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.02.011 · Cited by 2
Kawamura, K., Tsukada, N., Kimura, S., Kako, S., Minakata, D., Enami, T., Hamano, Y., Yamamoto, G., Ota, S., Obara, N., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70129 · Cited by 1
Self-citationCAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 2
Gavriatopoulou, M., Manganas, S., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.004 · Cited by 1
Self-citationJenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2
Wang, C., Xu, Z., Jiang, M., Chen, Y., & Lan, Y. (2025) · Cancers · doi:10.3390/cancers17213494 · Cited by 1
Identification and transformation of novel targets for immunotherapy in multiple myeloma
Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 2
“[97] HDP-101 is an innovative ADC targeting BCMA.”
Metadata
- Authors
- Dimopoulos, M. A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., Spicka, I., Radocha, J., Robak, P., Kim, K., Cavo, M., Suzuki, K., Morris, K., Pompilus, F., Phillips-Jones, A., Zhou, X. L., Fulci, G., Sule, N., Kremer, B. E., Opalinska, J., Mateos, M.-V., & Trudel, S.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- From the Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens (M.A.D.), and General Hospital Evangelismos (S.D.) — both in Athens; the Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey (M.B.); the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the First Faculty of Medicine, Charles University, and General Hospital, Prague (I.S.), and the Fourth Department of Internal Medicine–Hematology, University Hospital Hradec Králové, and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové (J.R.) — all in the Czech Republic; Leningrad Regional Clinical Hospital, Saint Petersburg, Russia (V.V.); the University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia (H.Q.); Medical University of Lodz, Łódź, Poland (P.R.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); IRCCS Azienda Ospedaliero–Universitaria di Bologna, Seràgnol...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-08
- Volume
- 391
- Issue
- 5
- Pages
- 408-421
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399275686
- Cited by
- 189
- References
- 17
- Citations by year
- 2026: 79 · 2025: 86 · 2024: 24
- FWCI
- 58.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- belantamab mafodotin, pomalidomide, dexamethasone, relapsed/refractory multiple myeloma, lenalidomide-refractory disease, anti-CD38 monoclonal antibody, bortezomib, progression-free survival, ocular adverse effects, triplet therapy, immunomodulators, proteasome inhibitors
- MeSH terms
- Bortezomib, Lenalidomide, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Eye Diseases, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, Thalidomide, Treatment Outcome, Disease Progression, Drug Resistance, Neoplasm, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.